Research map: The Evolving Landscape of Pulmonary Hypertension Treatment: From Vasodilation to Disease Modification

Back to the article

Papers in this map

  1. Initial Use of Ambrisentan plus Tadalafil in Pulmonary Arterial Hypertension · Nazzareno Galiè · 2015 · 1188 citations · Cited by this paper
  2. Human Pharmacokinetic Prediction of Antibody‐Drug Conjugates Using Human FcRn Transgenic Mice · 2026 · Related
  3. Pulmonary Arterial Hypertension · Paul M. Hassoun · 2021 · 747 citations · Cited by this paper
  4. From Pharmacodynamic Biomarker to Evaluating Treatment Response: Biomarkers in Primary Mitochondrial Diseases · 2026 · Related
  5. Phase 3 Trial of Sotatercept for Treatment of Pulmonary Arterial Hypertension · Marius M. Hoeper · 2023 · 728 citations · Cited by this paper
  6. Deep‐Learning: An Emerging Tool to Support Model‐Informed Drug Development · 2026 · Related
  7. Inhaled Treprostinil in Pulmonary Hypertension Due to Interstitial Lung Disease · Aaron B. Waxman · 2021 · 651 citations · Cited by this paper
  8. CYP2C19 c. 681G >A Is not in Complete Linkage Disequilibrium With c.332‐ 23A >G: Implications for Pharmacogenetic Testing · 2026 · Related
  9. Pulmonary Hypertension Due to Left Heart Diseases · Jean‐Luc Vachiéry · 2013 · 637 citations · Cited by this paper
  10. A Generative AI Framework for Pharmacokinetic Clinical Study Report Authoring · 2026 · Related
  11. Sotatercept for the Treatment of Pulmonary Arterial Hypertension · Marc Humbert · 2021 · 617 citations · Cited by this paper
  12. Model‐Informed Development of a Subcutaneous Formulation of Tislelizumab: Phase 1 Pharmacokinetics in Patients With Cancer · 2026 · Related
  13. The Giessen Pulmonary Hypertension Registry: Survival in pulmonary hypertension subgroups · Henning J. Gall · 2017 · 316 citations · Cited by this paper
  14. Challenges in Implementing Revocation of Oncology Drugs Under Conditional Early Approval in Japan: Regulatory Insights From Comparisons With FDA / EMA · 2026 · Related
  15. ACTRIIA-Fc rebalances activin/GDF versus BMP signaling in pulmonary hypertension · Lai‐Ming Yung · 2020 · 245 citations · Cited by this paper
  16. Evaluation of a Novel Peptide‐Based ELISA for the Serological Diagnosis of Trypanosoma cruzi Infection · 2026 · Related
  17. PATENT PLUS: a blinded, randomised and extension study of riociguat plus sildenafil in pulmonary arterial hypertension · Nazzareno Galiè · 2015 · 188 citations · Cited by this paper
  18. Drug Interactions of Vebreltinib, a Novel Type I c‐Met Inhibitor, Coadministration With Rifampin or Itraconazole in Healthy Participants · 2026 · Related
  19. PVDOMICS · Anna Ryan Hemnes · 2017 · 175 citations · Cited by this paper
  20. Pulmonary Hypertension Due to Left Heart Disease · Mohammed S. Al-Omary · 2020 · 155 citations · Cited by this paper
  21. Sotatercept in Patients with Pulmonary Arterial Hypertension at High Risk for Death · Marc Humbert · 2025 · 154 citations · Cited by this paper
  22. The actions of relaxin on the human cardiovascular system · Mohsin Sarwar · 2016 · 109 citations · Cited by this paper
  23. Evaluation and Management of Chronic Thromboembolic Pulmonary Hypertension · Jenny Z. Yang · 2023 · 101 citations · Cited by this paper
  24. Sotatercept for Pulmonary Arterial Hypertension within the First Year after Diagnosis · Vallerie V. McLaughlin · 2025 · 61 citations · Cited by this paper
  25. Effects of sildenafil on symptoms and exercise capacity for heart failure with reduced ejection fraction and pulmonary hypertension (the SilHF study): a randomized placebo‐controlled multicentre trial · Trond J. Cooper · 2022 · 45 citations · Cited by this paper
  26. MicroRNAs in Pulmonary Hypertension, from Pathogenesis to Diagnosis and Treatment · Junhua Xu · 2022 · 34 citations · Cited by this paper
  27. Survival, morbidity, and quality of life in pulmonary arterial hypertension patients: a systematic review of outcomes reported by population-based observational studies · Stefan Reinders · 2024 · 32 citations · Cited by this paper
  28. Novel composite clinical endpoints and risk scores used in clinical trials in pulmonary arterial hypertension · Olivier Sitbon · 2020 · 24 citations · Cited by this paper
  29. Sotatercept for Combined Post- and Precapillary Pulmonary Hypertension Associated With Heart Failure: Results From the Phase 2, Randomized, Placebo-Controlled CADENCE Study · Mardi Gomberg‐Maitland · 2026 · 18 citations · Cited by this paper
  30. New therapies in pulmonary arterial hypertension: Recent insights · Giulia Guglielmi · 2025 · 13 citations · Cited by this paper
  31. Management of Pulmonary Arterial Hypertension: Current Strategies and Future Prospects · Munish Sharma · 2025 · 13 citations · Cited by this paper
  32. Evolution and optimization of clinical trial endpoints and design in pulmonary arterial hypertension · Marco A. Caccamo · 2023 · 12 citations · Cited by this paper
  33. Therapeutic Potential of Treprostinil Inhalation Powder for Patients with Pulmonary Arterial Hypertension: Evidence to Date · Steven J. Cassady · 2024 · 10 citations · Cited by this paper
  34. Biomarkers for the prognosis of pulmonary arterial hypertension: Holy grail or flying circus? · Frédéric Lador · 2014 · 10 citations · Cited by this paper
  35. Oral Levosimendan for the Treatment of Pulmonary Hypertension due to Heart Failure With Preserved Ejection Fraction: Rationale and Design of the LEVEL Trial · Hidenori Yaku · 2025 · 8 citations · Cited by this paper
  36. Relaxin Mimetic in Pulmonary Hypertension Associated with Left Heart Disease: Design and Rationale of Re-PHIRE · Marcin Ufnal · 2025 · 6 citations · Cited by this paper
  37. Phase 2b trial of an oral relaxin family peptide receptor 1 agonist in patients with chronic heart failure: rationale and design · Macarena P. Quintana‐Hayashi · 2026 · 2 citations · Cited by this paper
  38. Abstract 4139216: The tolerability, safety, pharmacokinetics, and pharmacodynamics of TX000045, a long-acting Fc-relaxin fusion protein after single doses in healthy volunteers · Marcella K. Ruddy · 2024 · 1 citation · Cited by this paper

Source: OpenAlex (CC0)